Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.52 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 13/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 11/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.49 |
| ▸ | TYMP | P19971 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4387787 | 0.93 | TYMP (0.53) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL13589363 | 0.93 | TYMP (0.53) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL2580691 | 0.92 | P2RY2 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4085510 | 0.90 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL8332109 | 0.90 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL10592428 | 0.86 | TYMP (0.53) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL6758700 | 0.86 | DUT (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL2577905 | 0.86 | DUT (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL7922849 | 0.86 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL6323744 | 0.86 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023105281-A1 | SOLUBLE TIGIT RECOMBINANT PROTEINS | FUNDACIÒ PRIVADA INSTITUT DE RECERCA DE LA SIDA-CAIXA (ES) | 2023-06-15 | — | — | WO | disclosed |
| WO-2022165386-A1 | LNP AND LMP DELIVERY OF ANTIVIRAL NUCLEOTIDE 5'-PHOSPHATES | VIRBIS LLC (US) | 2022-08-04 | — | — | WO | disclosed |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2018-10-16 | — | — | US | disclosed |
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | GILEAD SCIENCES, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PHARMASSET, INC. | 2011-11-03 | — | — | US | disclosed |
| EP-1411954-B1 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET INC (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2251015-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | Pharmasset, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-1411954-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | Pharmasset Limited (BB) | 2004-04-28 | — | — | EP | disclosed |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | PHARMASSET, INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2002032920-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET LIMITED (BB) | 2002-04-25 | — | — | WO | disclosed |
| US-5625030-A | ESTERIFICATION OF HYDROXY ACIDS JOINED TO SUPPORT, PROTECTING AND DEPROTECTING | METABOLIX, INC. (US) | 1997-04-29 | — | — | US | disclosed |
| WO-1995018781-A1 | METHODS FOR SYNTHESIZING OLIGOMERS CONTAINING HYDROXY ACID UNITS | METABOLIX, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | SLC29A1, PNP, SLC29A2 | SLC28A1 14/4885SLC28A2 28/4885SLC29A1 1/4885 |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PNP, ALPP, XDH | SLC28A1 104/4885SLC28A2 177/4885SLC29A1 13/4885 |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, SLC29A2, PNP | SLC28A1 8/4885SLC28A2 17/4885SLC29A1 1/4885 |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, PNP, SLC29A2 | SLC28A1 13/4885SLC28A2 29/4885SLC29A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.